ClinicalTrials.gg
RecruitingNCT07698951PROTEA-PFO OUSUpdated Nov 19, 2026

Evaluating Percutaneous Repair Of The Atrial Septum With A Novel PFO Occluder: The PROTEA-PFO OUS Study

An interventional study of Recross P3 Occluder (P3O) System in PFO, PFO - Patent Foramen Ovale and Cryptogenic Stroke, sponsored by Recross Cardio, Inc.. Recruiting at 2 sites in Serbia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Recross Cardio, Inc. · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 19, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it aims to answer is:

  • Is the P3 Occluder System safe and effective for closing a PFO in patients who have had a stroke that could be related to a PFO.

Participants will:

  • Undergo the procedure to implant the P3 Occluder System, if deemed appropriate.
  • Visit their doctor at 1 month, 3 months, 6 months, and 1 year after the procedure for follow up exams.
  • Answer a phone call from study staff at 2 years and 3 years after the procedure to answer a survey.
02

Conditions studied

  • PFO
  • PFO - Patent Foramen Ovale
  • Cryptogenic Stroke
  • Patent Foramen Ovale
  • PFO-associated Stroke

Keywords

  • Patent Foramen Ovale
  • PFO
  • Cryptogenic Stroke
  • PFO Occluder
  • Transcatheter
  • PFO-associated stroke
03

In context

Foramen Ovale, Patent

137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

This study's planned enrollment of 15 is below the median of 154 across 69 interventional studies indexed under Foramen Ovale, Patent.

Browse Foramen Ovale, Patent studies →

Lead sponsor

Recross Cardio, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be ≥ 18 and ≤ 65 years of age
  2. Diagnosis of PFO, defined as visualization of microbubbles per TEE in the left atrium within three cardiac cycles from the right atrial opacification demonstrating right-to-left shunting at rest and/or during Valsalva release.
  3. Ischemic stroke, defined as acute focal neurological deficit, presumed to be due to focal ischemia and confirmed by MRI or CT to have a neuroanatomically relevant cerebral infarct.
  4. Modified Rankin score (mRS) ≤ 3.
  5. Appropriate PFO anatomy for implantation of the device as evaluated and determined by independent committee.
  6. Patient is willing and capable of providing .
  7. Prior to index procedure (7-day window), persons of must have a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  1. Other identifiable causes of stroke, including but not limited to aortic arch plaques (protruding >4 mm into the lumen), large artery atherosclerotic disease proximal to the territory of the index stroke, an established cardioembolic source, small-vessel occlusive disease, or arterial dissection, presence of left atrial appendage thrombus.
  2. Other arteriopathy of the intracranial or extracranial vessels with >50% stenosis proximal to the territory of the index stroke.
  3. Intracardiac thrombus or tumor.
  4. Myocardial Infarction (MI) or unstable angina within the previous 180 days.
  5. \< 2 years.
  6. Left ventricular aneurysm or akinesis.
  7. Moderate to severe mitral valve stenosis or severe mitral regurgitation.
  8. Aortic valve stenosis (mean gradient >20 mmHg) or severe regurgitation.
  9. Active endocarditis or other infection that may preclude implantation of the device.
  10. Any valve vegetation or Lambl's excrescence of any left-sided valve.
  11. Left ventricular dilated cardiomyopathy with \<35%.
  12. Another source of right-to-left shunts identified at baseline, including an atrial septal defect and/or fenestrated septum and pulmonary arteriovenous malformation.
  13. History of atrial tachycardia, atrial fibrillation or flutter, AV block, or ventricular arrhythmia requiring antiarrhythmic medication, pacemaker, or AICD.
  14. Severe renal failure ( Stage 4 CKD, \<30) or patient requiring dialysis.
  15. Severe liver disease (e.g., documented cirrhosis or active hepatitis).
  16. Severe lung insufficiency (e.g., need for supplemental oxygen or chronic medications).
  17. Uncontrolled hypertension, defined as sustained elevated blood pressure >140/90 mm Hg.
  18. Severe pulmonary artery hypertension, defined as pulmonary systolic pressure of >50mmHg.
  19. Uncontrolled hyperglycemia, defined as value >8% (IFCC: >64 mmol/mol).
  20. Increased bleeding risk such as severe liver failure, active peptic ulcer, proliferative diabetic retinopathy, history of severe bleeding (e.g.: gastrointestinal bleeding, macroscopic hematuria, intraocular bleeding, intracranial or cerebral hemorrhage), or other history of bleeding or coagulopathy.
  21. Known hypercoagulable state that would require full anticoagulation. Minimum testing to include lupus anticoagulant, anticardiolipin antibodies, beta-2-glycoprotein, homocysteine.
  22. Subjects for aspirin or clopidogrel.
  23. Subjects not able to discontinue anticoagulation for indications other than then index stroke.
  24. Any disorder in the investigator's opinion that could interfere with compliance of safety evaluation or require premature discontinuation of antiplatelet regime post-implantation, as well as any severe concurrent illness that would limit life expectancy (e.g., ).
  25. Currently an active subject in an investigational drug or device study that could confound the results of this study.
  26. Any significant valve dysfunction that contraindicates PFO closure or increased pulmonary vascular resistance/severe pulmonary hypertension.
  27. Contraindication for transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE).
  28. Any prior percutaneous cardiovascular intervention for AF ablation.
  29. Known nickel allergy that, in the opinion of the investigator, poses a safety risk with regards to participation in the trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Recross P3 Occluder (P3O) System

    The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.

    Device: Recross P3 Occluder (P3O) System

Interventions

  • DeviceRecross P3 Occluder (P3O) System

    The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.

06

What researchers measure

Primary outcomes

  1. Effective PFO Closure

    Effective PFO Closure, at index procedure and at 6 months as measured by TEE, as adjudicated.

    Time frame: 6 months

  2. Adverse Cardiovascular Events

    Occurrence of significant adverse events including cardiac death, myocardial infarction, and stroke within 30 days post-procedure

    Time frame: 30 days

Secondary outcomes

  1. Rate of device-related or procedure-related Serious Adverse Events (SAEs)

    Rate of device-related or procedure-related Serious Adverse Events (SAEs) at 30 days. Rate of device-related or procedure-related Serious Adverse Events (SAEs) at 6 months.

    Time frame: 30 days; 6 months

  2. Correct device position

    Correct device position as assessed at 6 months on echocardiography, assessed by TTE or TEE.

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

Of 31 interventional studies with no phase under Foramen Ovale, Patent, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 100. This study's planned 14 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jul 2027 → Aug 2027 and completion Dec 2029 → Feb 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
Jul 13, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Aug 2027was Jul 2027
CompletionEst.
Feb 2030was Dec 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Institute for Cardiovascular Diseases of Vojvodina · Kamenitz, Serbia
Nov 19, 2026
Primary completion
Jul 2027→Aug 2027
Nov 19, 2026
Study completion
Dec 2029→Feb 2030
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    1 site added
    Show site
    • Institute for Cardiovascular Diseases of Vojvodina · Kamenitz, Serbia
    Primary completion Jul 2027→Aug 2027
    Study completion Dec 2029→Feb 2030
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07698951
Lead sponsor
Recross Cardio, Inc.
Collaborators
SCIRENT Clinical Research and Science d.o.o.
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Jun 17, 2026
Primary completion
Aug 2027 (estimated)
Completion
Feb 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

VP, Clinical Affairs
Contact
clinical@recrosscardio.com
1.646.583.0352

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion